Consensus Intellia Therapeutics, Inc.

Stocks

NTLA

US45826J1051

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-30 EDT			5-day change	1st Jan Change
12.47 ^USD	-5.74%		+11.24%	+38.71%

10-13	Intellia Therapeutics, Inc. Announces Appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, Effective October 26, 2026	CI
10-06	Barclays Initiates Intellia Therapeutics at Underweight With $8 Price Target	MT

Evolution of the Average Target: Intellia Therapeutics, Inc.

Evolution of the Target Price: Intellia Therapeutics, Inc.

Changes in Analyst Recommendations: Intellia Therapeutics, Inc.

f074c0505007591.TprchbaRRQEywcF0pKYcGUzf_twj-oMr-z4niMxq2Pc.NKiZ1OXCDWdcrocDxcpMVzScuOVSoNxlymEU8JoysZk52OrV_NwsdUWlqg~1cb7cfa5ba243ab9e2f30ff5d339651c

Analysts' recommendations: Intellia Therapeutics, Inc.

10-06	Barclays Initiates Intellia Therapeutics at Underweight With $8 Price Target	MT
09-08	Wedbush Adjusts Intellia Therapeutics Price Target to $13 From $12, Maintains Neutral Rating	MT
08-06	Wedbush Adjusts Intellia Therapeutics Price Target to $12 From $17, Maintains Neutral Rating	MT
07-09	Wedbush Raises Intellia Therapeutics Price Target to $17 From $12, Maintains Neutral Rating	MT
04-28	Chardan Lifts Price Target on Intellia Therapeutics to $30 From $27, Keeps Buy Rating	MT
03-03	Chardan Raises Price Target on Intellia Therapeutics to $27 From $26, Keeps Buy Rating	MT
03-03	RBC Raises Price Target on Intellia Therapeutics to $15 From $9, Keeps Sector Perform, Speculative Risk	MT
03-02	William Blair Upgrades Intellia Therapeutics to Outperform From Market Perform	MT
03-02	Global markets live: Amazon, AWS, Lufthansa, Saudi Aramco, Standard Chartered…
02-27	Wedbush Raises Price Target on Intellia Therapeutics to $12 From $7, Keeps Neutral Rating	MT
01-06	BofA Adjusts Price Target on Intellia Therapeutics to $12 From $14, Maintains Neutral Rating	MT
11-11	Jones Downgrades Intellia Therapeutics to Neutral From Buy	MT
11-11	Evercore ISI Downgrades Intellia Therapeutics to In Line From Outperform, Adjusts PT to $8 From $17	MT
11-10	Intellia Therapeutics, Inc. Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin Amyloidosis with Cardiomyopathy	CI
11-10	Truist Cuts Price Target on Intellia Therapeutics to $14 From $25, Keeps Buy Rating	MT
11-07	RBC Adjusts Price Target on Intellia Therapeutics to $9 From $14, Maintains Sector Perform Rating	MT
11-07	JPMorgan Downgrades Intellia Therapeutics to Underweight From Neutral, Adjusts Price Target to $5 From $12	MT
25-10-31	Intellia Stock Downgraded After Trial Pause Raises Safety Concerns, BofA Says	MT
25-10-28	Intellia Therapeutics' Liver Toxicity Claim in Phase 3 Trials 'Unconvincing,' RBC Says	MT
25-10-28	Chardan Cuts Price Target on Intellia Therapeutics to $48 From $60, Keeps Buy Rating	MT
25-10-28	William Blair Downgrades Intellia Therapeutics to Market Perform From Outperrorm	MT
25-10-28	Wells Fargo Downgrades Intellia Therapeutics to Equal Weight From Overweight, Adjusts Price Target to $17 From $45	MT
25-10-28	RBC Downgrades Intellia Therapeutics to Sector Perform From Outperform, Cuts Price Target to $14 From $21, Keeps Speculative Risk	MT
25-10-27	Intellia Therapeutics Shares Fall After Pausing Patient Dosing, Screening in Phase 3 Nex-Z Trials	MT
25-10-27	Intellia Therapeutics provides update on Magnitude clinical trials of Nexiguran Ziclumeran	RE

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	INTELLIA THERAPEUTICS, INC.					+85.33%
	WUXI APPTEC CO., LTD.					+42.48%
	ARGENX SE					+24.46%
	LONZA GROUP AG					+8.88%
	IQVIA HOLDINGS INC.					+16.51%
	BEONE MEDICINES AG					+18.16%
	REVOLUTION MEDICINES, INC.					+35.3%
	GENMAB A/S					+1.94%
	CELLTRION, INC.					+41.27%
	INSMED INCORPORATED					+72.28%
	Average					+34.66%
	Weighted average by Cap.					+27.44%